We’ve seen tremendous progress in the field of cancer immunotherapy in recent years, and the potential now exists to improve on the benefits obtained with monotherapy by combining agents with complementary mechanisms of action.
More than 800 trials of immune-based combination therapies are underway; coupled with increasing opportunities for collaboration between the pharmaceutical and biotech industries, government and academia, the field is at an exciting juncture where the potential for novel therapeutic approaches has never been greater.
The SITC Combination Immunotherapies Task Force has convened to:
Journal for ImmunoTherapy of Cancer, February 2017
By summarizing the current status of combination immunotherapy, and addressing potential challenges in development and clinical implementation of combinatorial approaches, this paper provides evidence-based guidance to drive progress and improve on the clinical benefits obtained with single therapeutic agents. With greater understanding of the mechanisms of action of immunotherapy agents, and of the counter-defenses mounted by tumors, there is potential for novel combinations to increase the number of patients who respond to immunotherapy, the tolerability of treatment, and the duration of treatment response.
Patrick Ott, MD, PhD Dana-Farber Cancer Institute/Harvard Medical School
[Holbrook E. Kohrt, MD, PhD*] Stanford Cancer Institute
F. Stephen Hodi, MD Dana-Farber Cancer Institute
Howard L. Kaufman, MD, FACS Rutgers Cancer Institute of New Jersey
Drew M. Pardoll, MD, PhD Johns Hopkins University School of Medicine
Jon M. Wigginton, MD MacroGenics, Inc.
Jedd D. Wolchok, MD, PhD Memorial Sloan Kettering Cancer Center
*Holbrook Edwin Kidd Kohrt, MD, PhD (1977-2016) Dr. Kohrt had a significant impact on the field and brought his considerable scientific insights and incredible energy to every project. He was committed to the field of tumor immunology and immunotherapy and to the mission of SITC.
FDA approves first cancer treatment for any solid tumor with a specific genetic feature Do you know any commercially available kit for testing microsatellite instability in this (immunotherapy) context please? ------------------------------ Stergios ...
Don't miss Oncology Central 's FREE CME-accredited symposium on immuno-oncology. This virtual event features speakers such as James Gulley from the National Cancer Institute and Susan Slovins from Memorial Sloan Kettering Cancer Center.
Talks include ...
Did you know that through SITC Cancer Immunotherapy CONNECT you have the opportunity to ask questions of peers and colleagues from across the world?
Discuss the latest advancement in cancer immunotherapy, receive feedback on your line of work, ...
Indian FDA after clinical trials for DC immunotherapy has approved post marketing surveillance to be conducted by Delhi based research Biotech company in collaboration with oncologists. The roll out across India should start by May end. The license is ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org